# Oncolytic Virus Plus PD-1 Inhibitor to Patients With Advanced Pancreatic Cancer

Source: https://onco.cc/trials/nct06196671/  
OnCo record `nct06196671` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of h101 oncolytic adenovirus and camrelizumab in pancreatic cancer, run by Fudan University, not yet recruiting.

## Summary

Oncolytic Virus Plus PD-1 Inhibitor to Patients With Advanced Pancreatic Cancer is a phase 2, interventional study registered as NCT06196671 by Fudan University, with a registry enrolment figure of 30 participants, started 2026-12-01 and due to reach its primary completion in 2028-01-01. Interventions recorded: H101; Camrelizumab. Conditions listed: Pancreatic Cancer. Primary outcome: Overall survival，OS. Pancreatic eligibility wording from the registry: "* Histologically or cytologically confirmed advanced pancreas adenocarcinoma". No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Also known as: PTCA199-8
- Tags: ctgov-ingest; pancreatic-deep-dive
- Registry id: NCT06196671
- Phase: 2
- Setting: Oncolytic Virus Plus PD-1 Inhibitor to Patients With Advanced Pancreatic Cancer
- Sponsor: Fudan University
- Enrolled: 30

## Sources

- ClinicalTrials.gov NCT06196671: https://clinicaltrials.gov/study/NCT06196671

## Connected records

- cancers: [Metastatic pancreatic ductal adenocarcinoma](https://onco.cc/cancers/metastatic-pdac/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- drugs: [Camrelizumab](https://onco.cc/drugs/camrelizumab/), [H101 oncolytic adenovirus](https://onco.cc/drugs/h101-oncolytic-adenovirus/)
- terms: [Pancreatic cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/pancreatic-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06196671.json